Welcome, Guest
Username: Password: Remember me
The Company
  • Page:
  • 1

TOPIC: Annually recurring biotech madness in SF this week

Annually recurring biotech madness in SF this week 11 Jan 2015 10:30 #3144

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3332
  • Thank you received: 1114
JP Morgan is calling its clients, partners and what have you to San Francisco again in the second full week of the year and all kinds of smaller events and meeting are held "surrounding" this, where medium size, smaller size and tiny tiny size Companies like Cytori also are presenting.

For Cytori- who´s webpage cannot keep pace with present ongoings or which cost has been fallen victim to the red "pencil" lol - here some help:



Next week Cytori will be at TWO events:

First - tomorrow jan 12 2015-

Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the company has been selected to present at the Biotech Showcase™ at 3:30 PM Pacific Time (6:30 PM Eastern Time) on Monday, January 12, 2015. The presentation will take place in the C-Mission II room at the Parc 55 Wyndham Hotel in San Francisco.
Marc Hedrick, CEO and President of Cytori Therapeutics, will provide an update on current corporate activities and recent developments, including its recently announced STAR trial.
On December 10, 2014, Cytori announced its plan to begin a US pivotal trial, the STAR trial, designed to evaluate the efficacy of Cytori Cell Therapy™ in treating impairment in hand function due to scleroderma. Further details regarding the therapy and planned trial will be presented at the conference.
A live audio webcast of the presentation will be available under the investor relations section of Cytori’s website at www.cytori.com . A replay of the presentation will be available for 30 days following the event. Please connect to Cytori’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Biotech Showcase
The Biotech Showcase 2015 Conference ( www.ebdgroup.com/bts ) is one of the most significant healthcare investor conferences of the year. It is designed to provide private and public biotechnology and life sciences companies the opportunity to present to, and meet with, public and private investors, and pharmaceutical executives. This is the 7th year for the Biotech Showcase. More than 1700 investors and biopharmaceutical executives from around the world are expected to attend.



Second - later that week on Wednesday 14 Jan 2015:

Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces it will be hosting an information session dedicated to its planned STAR pivotal trial and scleroderma, featuring principal investigator Dr. Dinesh Khanna. The session will be held on January 14, 2015, from 1:30 PM to 4:30 PM at the Prescott Hotel, 545 Post Street, San Francisco, Room 736.
The STAR pivotal trial is expected to commence in 2015 and will evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma, a rare autoimmune disease affecting approximately 50,000 people in the United States.
The January 14th informational session will provide an opportunity to understand the epidemiology of scleroderma and the planned trial design, to review previous trial data and other scientific support, and to learn about the scleroderma market opportunity.

The following user(s) said Thank You: mtpinman, d9dozrman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Annually recurring biotech madness in SF this week 12 Jan 2015 09:12 #3151

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3332
  • Thank you received: 1114
On December 10 2014- the announcement was made about the CONDITIONAL approval for the pivotal trial.

Now the approval is - I presume- not conditional any longer

January 12, 2015
SAN DIEGO - Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that the Center for Biologics Evaluation and Research (CBER), a division of the U.S. Food and Drug Administration (FDA), has given final approval to its application for an Investigational Device Exemption (IDE) to begin a pivotal trial (the “STAR trial”) to evaluate Cytori Cell Therapy™ as a potential treatment for impaired hand function in scleroderma.
“We are pleased to be one step closer to bringing cell therapy into the mainstream of medicine,” said Marc H. Hedrick, M.D. President and CEO of Cytori Therapeutics. “The pilot trial data showed evidence that our lead therapeutic could substantially improve hand function and overall quality of life in this group of patients that today have limited effective therapeutic options.”
The STAR trial will begin enrolling in 2015 and will include 80 patients, in up to 12 centers in the United States. The trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of a single administration of Cytori’s lead cellular therapeutic, ECCS-50, in scleroderma patients with hand dysfunction. The impairment in hand function is typically progressive and can result in chronic pain, blood flow changes and often profound disability. The available treatments often have minimal impact and those for advanced disease are often accompanied by significant adverse effects.
“We are extremely excited about the approval of the STAR trial. Dr. Dinesh Khanna, one of the principal investigators, is a widely respected international scleroderma expert, and his participation is a strong endorsement of this trial. The International Scleroderma Network welcomes this novel therapeutic approach, which aims to improve scleroderma hand function. If this advanced cell therapy by Cytori Therapeutics proves effective, this will represent a unique and deeply needed option for patients,” said Shelley Ensz, Founder and President, International Scleroderma Network.
Dr. Hedrick will provide an update on current corporate activities and developments, including this recently announced STAR trial, at Biotech Showcase on Monday, January 12 at 3:30 PM Pacific Time, in room C-Mission 11 at the Parc 55 Wyndham Hotel, San Francisco.
A live audio webcast of the presentation will be available under the investor relations section of Cytori’s website at www.cytori.com . A replay of the presentation will be available for 90 days following the event. Please connect to Cytori’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.
Additionally, Cytori will be hosting an information session dedicated to its planned STAR trial and scleroderma and featuring Dr. Khanna. The session will be held on Wednesday, January 14, 2015 from 1:30 PM to 4:30 PM, at the Prescott Hotel, 545 Post Street, San Francisco. Please contact Shawn Richardson at This email address is being protected from spambots. You need JavaScript enabled to view it. for more information.
A live audio webcast of Dr. Khanna’s scleroderma and STAR trial related remarks will also be available under the investor relations section of Cytori’s website at www.cytori.com . A replay of the presentation will be available for 90 days following the event.
About Dr. Dinesh Khanna
Dinesh Khanna, M.D., M.S., Marvin & Betty Danto Research Professor of Connective Tissue Research and Associate Professor of Internal Medicine in the Division of Rheumatology, is the director of the University of Michigan Scleroderma Program. He has also served as Clinical Director of UCLA’s Scleroderma Clinic.
Dr. Khanna is the author of over 160 peer-reviewed publications and book chapters. He has won numerous awards, including the 2007 Spirit of Leadership Award and the 2011 “Best Doctor of the Year” award from the Scleroderma Foundation. He is board certified in rheumatology. Dr. Khanna is currently funded by the National Institutes of Health and is particularly interested in the design of clinical trials and assessing patient reported outcomes in patients with scleroderma and leading novel international clinical trials in scleroderma.
Dr. Khanna is a fellow of the American College of Rheumatology. He was elected by his peers to the 2011-2012 Best Doctors in America, which recognizes the area’s top clinicians.


The new IR man is named : Shawn Richardson.
The following user(s) said Thank You: d9dozrman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Annually recurring biotech madness in SF this week 12 Jan 2015 12:24 #3155

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3332
  • Thank you received: 1114

of a single administration of Cytori’s lead cellular therapeutic, ECCS-50, in scleroderma patients with hand dysfunction


Our fat cells now seem to have a "product name"- ECCS-50...

Now all we have to know what the abbreviation ECCS stands for. I read something about "evaluation models", but that is surely not meant.

maybe Hedrick explains that in his update later tonight. Since that is in the early hours European time- I hope other board members listen and provide an update.

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.088 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites